Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Subjects

Next Previous
Search
Trial Profile

A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimodivir (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 01 Sep 2017 Results assessing effect of JNJ-63623872 on cardiac repolarization interval in healthy adults, were published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology, ACCP 2017.
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 15 Jun 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top